Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03870451 · ClinicalTrials.gov registry record · NA
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03870451 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants.
The verdict
NCT03870451, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.
Interventions
- DEVICE VascuTherm5 vascular compression device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2023-02-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03870451
The ClinicalTrials.gov registry entry for NCT03870451 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VascuTherm5 vascular compression device is the first listed.
NCT03870451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03870451 about?
NCT03870451 is a clinical study titled "Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma". This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of lif...
What is the current status of trial NCT03870451?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2019-11-01. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT03870451?
The interventions under investigation include: VascuTherm5 vascular compression device (DEVICE).
Who is sponsoring clinical trial NCT03870451?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.